Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden

S J Panchal, P Müller-Schwefe, J I Wurzelmann, S J Panchal, P Müller-Schwefe, J I Wurzelmann

Abstract

As a result of the undesired action of opioids on the gastrointestinal (GI) tract, patients receiving opioid medication for chronic pain often experience opioid-induced bowel dysfunction (OBD), the most common and debilitating symptom of which is constipation. Based on clinical experience and a comprehensive MEDLINE literature review, this paper provides the primary care physician with an overview of the prevalence, pathophysiology and burden of OBD. Patients with OBD suffer from a wide range of symptoms including constipation, decreased gastric emptying, abdominal cramping, spasm, bloating, delayed GI transit and the formation of hard dry stools. OBD can have a serious negative impact on quality of life (QoL) and the daily activities that patients feel able to perform. To relieve constipation associated with OBD, patients often use laxatives chronically (associated with risks) or alter/abandon their opioid medication, potentially sacrificing analgesia. Physicians should have greater appreciation of the prevalence, symptoms and burden of OBD. In light of the serious negative impact OBD can have on QoL, physicians should encourage dialogue with patients to facilitate optimal symptomatic management of the condition. There is a pressing need for new therapies that act upon the underlying mechanisms of OBD.

References

    1. World Health Organization. Cancer Pain Relief. Geneva: WHO; 1996.
    1. Quigley C. The role of opioids in cancer pain. BMJ. 2005;331:825–9.
    1. Kalso E. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–80.
    1. The Pain Society. Recommendations for the Appropriate Use of Opioids for Persistent Non-cancer Pain. A Consensus Statement Prepared on Behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. (accessed 23 April 2007)
    1. Klepstad P. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med. 2005;19:477–84.
    1. Breivik H. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333.
    1. IMS Health National Prescription Audit
    1. IMS Health MIDAS database
    1. Choi YS. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002;24:71–90.
    1. Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007;16:181–94.
    1. Mehendale SR. Opioid-induced gastrointestinal dysfunction. Dig Dis. 2006;24:105–12.
    1. Moore RA. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046–51.
    1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11S–8S..
    1. Gutstein HB. Opioid Analgesics. New York, NY: McGraw Hill; 2001. (The Pharmacological Basis of Therapeutics)
    1. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage. 1990;5:362–7.
    1. Ballantyne JC. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943–53.
    1. Kurz A. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649–71.
    1. Sternini C. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004;16(Suppl. 2):3–16.
    1. Sanger GJ. The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modelling. Neurogastroenterol Motil. 2004;16(Suppl. 2):38–45.
    1. De Schepper HU. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16:383–94.
    1. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004;361:192–5.
    1. Shook JE. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther. 1987;243:492–500.
    1. De Luca A. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69:103–15.
    1. Wood JD. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16(Suppl. 2):17–28.
    1. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004;11:3–9.
    1. Basson M. Constipation. (accessed March 2007)
    1. Allan L, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322:1154–8.
    1. Klepstad P. Effects on cancer patients’ health-related quality of life after the start of morphine therapy. J Pain Symptom Manage. 2000;20:19–26.
    1. Meuser T. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. J Pain. 2001;93:247–57.
    1. Longstreth GF. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.
    1. Devulder J. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin. 2005;21:1555–68.
    1. Fallon M. Constipation in cancer patients: prevalence, pathogenesis and cost-related issues. Eur J Pain. 1999;3:3–7.
    1. Leslie J. Opioid-induced constipation compromises pain management and impacts patients quality of life. Anesthesiology. 2006;105 A1490.
    1. McNicol E, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231–56.
    1. Bell T, et al. The 25th Annual Scientific Meeting of the American Pain Society. San Antonia, TX, USA: OBD symptoms impair quality of life and daily activities, regardless of frequency and duration of opioid treatment: results of a US patient survey (PROBE survey)
    1. Bell T. Eur J Pain. Suppl. 1. Vol. 10. Istanbul, Turkey: 2006. Prevalence, severity and impact of opioid-induced GI side effects on the EU: results of a patient survey; p. S173.
    1. Annunziata K. Eur J Pain. Suppl. 1. Vol. 10. Istanbul, Turkey: 2006. Impact of opioid-induced constipation on patients and healthcare resource use; p. S172.
    1. Thorpe DM. Management of opioid-induced constipation. Curr Pain Headache Rep. 2001;5:237–40.
    1. Slappendel R. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain. 2006;10:209–17.
    1. Marquis P. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005;40:540–51.
    1. Hanks GW, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–93.
    1. Cherny N, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19:2542–54.
    1. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004:CD004847.
    1. Weschules DJ, et al. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients. Pain Med. 2006;7:320–9.
    1. Swegle JM. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74:1347–54.
    1. Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci. 2005;27:432–5.
    1. Überall M. Eur J Pain. Suppl. 1. Vol. 10. Istanbul, Turkey: 2006. Opioid-induced constipation – a frequent and distressing side effect in daily practice affecting oral and transdermal opioid applications; p. S172.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren